SAB Biotherapeutics (SABS) Institutional Ownership $1.70 +0.05 (+2.72%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for SAB Biotherapeutics (NASDAQ:SABS)CurrentInstitutional OwnershipPercentage7.82%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$859.96KNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$37.94M Get SABS Insider Trade Alerts Want to know when executives and insiders are buying or selling SAB Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SABS Institutional Buying and Selling by Quarter SAB Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/29/2025 Silver Oak Securities Incorporated20,188$30K0.0%N/A0.217% 4/21/2025 Silver Oak Securities Incorporated20,188$30K0.0%N/A0.217% 2/17/2025Millennium Management LLC29,411$112K0.0%-43.4%0.319% 2/14/2025Northern Trust Corp11,387$43K0.0%N/A0.123% 2/14/2025Diadema Partners LP30,000$114K0.0%N/A0.325% 2/12/2025Geode Capital Management LLC80,234$307K0.0%+18.8%0.869% 1/15/2025HB Wealth Management LLC237,400$982K0.0%+118.6%2.572% 11/15/2024Kovitz Investment Group Partners LLC19,201$52K0.0%N/A0.208% 11/15/2024RTW Investments LP635,276$1.72M0.0%-17.2%6.883% 7/17/2024 First PREMIER Bank19,386$60K0.0%N/A0.210% Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/16/2024BVF Inc. IL917,826$4.17M0.1%-90.0%9.944% 2/15/2024BVF Inc. IL9,178,282$6.31M0.2%N/A175.426% 2/14/2024Commodore Capital LP1,831,746$1.26M0.1%N/A35.024% 2/14/2024RTW Investments LP9,178,282$6.31M0.1%N/A175.493% 11/8/2023Pathstone Family Office LLC506,513$319K0.0%N/A0.968% 8/9/2023Institutional & Family Asset Management LLC192,027$159K0.0%+28.2%0.381% 2/2/2023 Silver Oak Securities Incorporated51,941$31K0.0%N/A0.121% 11/7/2022Institutional & Family Asset Management LLC149,774$105K0.0%+91.7%0.348% 10/20/2022 First PREMIER Bank807,535$566K0.2%+23.8%1.877% 8/15/2022LGL Partners LLC23,000$33K0.0%N/A0.054% 8/3/2022AE Wealth Management LLC18,700$27K0.0%N/A0.044% 7/26/2022 First PREMIER Bank652,440$946K0.3%N/A1.519% 5/9/2022Qube Research & Technologies Ltd24,179$91K0.0%+43.8%0.056% 2/14/2022Radcliffe Capital Management L.P.546,658$5.52M0.1%N/A1.257% 2/14/2022ETF Managers Group LLC13,202$105K0.0%N/A0.030% 2/14/2022Institutional & Family Asset Management LLC78,115$610K0.1%N/A0.180% 2/10/2022Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 2/9/2022Wolverine Asset Management LLC6,602$51K0.0%N/A0.015% 2/9/2022Alps Advisors Inc.50,306$393K0.0%N/A0.116% 2/3/2022Spectrum Management Group LLC5,030$39K0.0%N/A0.012% 2/1/2022Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 1/19/2022 First PREMIER Bank832,555$6.50M1.7%N/A1.915% 1/18/2022 Nadler Financial Group Inc.11,000$86K0.0%N/A0.025% 11/17/2021Tudor Investment Corp Et Al60,000$605K0.0%N/A0.406% (Data available from 1/1/2016 forward) SABS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SABS shares? During the previous two years, 13 institutional investors and hedge funds held shares of SAB Biotherapeutics. The most heavily invested institutionals were BVF Inc. IL ($4.17M), RTW Investments LP ($1.72M), Commodore Capital LP ($1.26M), HB Wealth Management LLC ($982K), Pathstone Family Office LLC ($319K), Geode Capital Management LLC ($307K), and Institutional & Family Asset Management LLC ($159K).Learn more on SABS's institutional investors. What percentage of SAB Biotherapeutics stock is owned by institutional investors? 7.82% of SAB Biotherapeutics stock is owned by institutional investors. Learn more on SABS's institutional investor holdings. Which institutional investors have been buying SAB Biotherapeutics stock? Of the 12 institutional investors that purchased SAB Biotherapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($9.18M), RTW Investments LP ($9.18M), Commodore Capital LP ($1.83M), Pathstone Family Office LLC ($506.51K), HB Wealth Management LLC ($128.80K), Institutional & Family Asset Management LLC ($42.25K), and Silver Oak Securities Incorporated ($40.38K). How much institutional buying is happening at SAB Biotherapeutics? Institutional investors have bought a total of 20,998,918 shares in the last 24 months. This purchase volume represents approximately $15.09M in transactions. Which SAB Biotherapeutics major shareholders have been selling company stock? The following institutional investors have sold SAB Biotherapeutics stock in the last 24 months: BVF Inc. IL ($8.26M), RTW Investments LP ($131.67K), and Millennium Management LLC ($22.54K). How much institutional selling is happening at SAB Biotherapeutics? Institutional investors have sold a total of 8,414,661 shares in the last 24 months. This volume of shares sold represents approximately $37.94M in transactions. Related Companies AGEN Institutional Ownership DOMH Institutional Ownership FBIO Institutional Ownership BOLT Institutional Ownership CRIS Institutional Ownership MTEM Institutional Ownership AMGN Institutional Ownership GILD Institutional Ownership VRTX Institutional Ownership REGN Institutional Ownership This page (NASDAQ:SABS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
